Lupin Limited, a leading global pharmaceutical company, has announced that its subsidiary, Lupin Atlantis Holdings SA, has entered into a distribution agreement with Celnova Pharma for the commercialization of its…
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company committed to improving the lives of patients with serious diseases, announced today that KarXT (a combination of xanomeline and…
Odyssey Therapeutics, Inc., a biotechnology firm at the forefront of developing next-generation precision immunomodulators for inflammatory conditions, has announced the establishment of its Scientific Advisory Board (SAB). This board features…
GE HealthCare (Nasdaq: GEHC) has received U.S. Food and Drug Administration (FDA) approval for Flyrcado™ (flurpiridaz F 18) injection, marking a significant advancement in positron emission tomography (PET) myocardial perfusion…
Artera, a pioneer in multimodal artificial intelligence (MMAI) for prognostic and predictive cancer testing, is set to present two oral abstracts at the 2024 American Society for Radiation Oncology (ASTRO)…
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi have announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) as an add-on maintenance treatment for adults with inadequately…
Bristol Myers Squibb (NYSE: BMY) has received approval from the U.S. Food and Drug Administration (FDA) for COBENFY™ (xanomeline and trospium chloride), marking a significant advancement in the treatment of…
The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with chronic obstructive pulmonary disease (COPD) who have an eosinophilic phenotype and…
AstraZeneca’s Tagrisso (osimertinib) has received U.S. approval for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), whose disease has…
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III REGENCY study of Gazyva®/Gazyvaro® (obinutuzumab) in patients with active lupus nephritis. The study revealed that…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced that the Phase 3 KEYFORM-007 trial, which investigated the fixed-dose combination of favezelimab (Merck’s anti-LAG-3 antibody) and…
BioAlberta is excited to announce a new partnership with AxialBridge as its operational and commercialization partner. This collaboration aims to assist Alberta-based biotechnology and MedTech companies in expanding their clinical…